March 19, 2016 9:16am

 

There is still risk in the sector as the iShares Nasdaq Biotechnology ETF (IBB) declined 4% for the week

 

Ranking Friday’s end-of-day pre-open trading indications – 2 hits and 1 misses.

Subscribe:  http://www.regmedinvestors.com/create-account   

 

 

There is one thing that everyone needs, and that's interpretation and translation of intelligence, not just news or information - we get too much!

  • To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy regenerative medicine portfolio to track and monitor its pricing metric;

The takeaway is that investor need to decide what actions to take, or not take, based on their specific situation.

 

 

U.S. stocks traded higher Friday, extending the rally that followed the Federal Reserve's accommodative policy decision on Wednesday. The major averages closed nearly 1 percent higher or more for the week, their fifth-straight week of gains since November.

The NASDAQ closed UP +20.66 or +0.43% to 4,795.65 and the DOW closed UP +120.81 or +0.69% to 17,602.30.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.

  • Friday, the stem, cell and gene therapy RegMed sector opened positive with an A/DL of 22/17 and 4 flats;
  • The mid-day stayed positive with an A/DL of 29/12 and 2 flats;
  • The closing bell rang positive with A/DL of 24/16 and 3 flat

 

 

Earnings update:

 

 

Henry’omics:

The stem, cell and gene therapy regenerative medicine (SCGT&RM) sector opened positive, stayed positive at the mid-day  and closed … positive (of 43 covered companies).

  • I didn’t notice any outsized increase in trade volume around options expiration as sector stocks changed direction through-out the session in a seemingly normal sequence.

One issue we should all be concerned about is slow trial enrollments combined with the lack of capital market access suggest that stocks won’t see as much or any large value moves in the so far difficult 2016.

  • I also don’t see many valuation enhancements in 2016, debt and ATM use is at an all-time high.

As we consider 2016 and going forward – consider headwinds!

 

 

Friday’s handicapping the sector pre-open indications – 2 hits and 1 miss: 

  • Applied Genetic Technologies (AGTC) closed UP +$0.31 – hit;
  • Capricor (CAPR) closed DOWN -$0.04 – hit;
  • Harvard Apparatus RT (HART) closed DOWN -$0.17 – miss;

 

 

Dosing the sector – what a day for the 43 Patients:

  • The market opened: POSITIVE with 17 decliners, 22 advancers and 4 flats;
  • The mid-day (12:30 pm: POSITIVE with 12 decliners, 29 advancers and 2 flats;
  • Closing bell: POSITIVE with 16 decliners, 24 advancers and 3 flats

 

 

Review my fear gauge or the CBOE Volatility Index (VIX) which is scary:

·         Friday above 14;

·         Thursday traded below 14;

·         Wednesday traded below 15.5;

·         Tuesday traded above 17;

·         Monday traded below 17;

·         Last, Friday traded below 17;

 

 

Riding the indexes and ETFs roller-coaster:

The iShares Biotechnology Stocks ETF (IBB) closed UP on Friday +4.25 or +1.72%

·         Thursday -3.11 or -1.24%

·         Wednesday -1.27 or -0.51%

·         Tuesday -9.97 or -3.81%

·         Monday -0.50 or -0.19%

·         Last, Friday closed up +6.86 or +2.69%;

The NASDAQ Biotechnology index (NBI) closed UP on Friday +46.39 or +1.80%

·         Thursday -31.69 or -1.21%

·         Wednesday -13.26 or -0.50%

·         Tuesday -105.31 or -3.85%

·         Monday -5.54 or -0.20%

·         Last, Friday closed up +71.65 or +2.69%

The Russell 2000 (IWM) closed UP on Friday +0.98 or +0.90%

·         Thursday +1.64 or +1.53%

·         Wednesday +1.75 or +0.71

·         Tuesday -1.68 or -1.56%

·         Monday -0.28 or -0.26%

·         Last, Friday closed UP +2.27 or +2.14%;

The SPDR SD&P Biotech ETF (XBI) closed UP on Friday

·         Thursday +0.16 or +0.33%

·         Wednesday -0.58 or -1.19%

·         Tuesday -3.00 or -5.78%

·         Monday +0.59 or +1.15%

·         Last, Friday closed up +1.66 or +3.34%

 

 

Who was leading the declines – to of the bottom 5?

  • bluebird bio (BLUE) closed down -$0.82 to $44.64;
  • Regenxbio (RGNX) -$0.35 to $11.62;
  • Kite Pharma (KUITE) -$0.27 to $44.33;
  • Mesoblast (MESO) -$0.20 to $10.34;
  • Harvard Apparatus RT (HART) -$0.18 to $1.70;

 

 

Who was UP – top 5:

  • Cellectis ADR (CLLS) closed up +$1.66 to $27.17;
  • Spark therapeutics (ONCE) +$1.60 to $34.99;
  • Intrexon (XON) +$1.60 to $37.38;
  • Juno Therapeutics (JUNO) +$1.39 to $39.44;
  • uniQure (QURE) closed up +$0.70 to $11.84;

 

 

Who was FLAT?

  • Brainstorm (BCLI) ay $2.75;
  • Opexa (OPXA) at $2.08;
  • ReNeuron (RENE.L) at $3.125;

 

 

“Venimus, emimus, vendidit et resurrexit” – the new mantra, we came, we bought, we sold and we came back again!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.